Health Affairs, 26, no. 3 (2007): 790-799 doi: 10.1377/hlthaff.26.3.790 © 2007 by Project HOPE	New Online   Senate Health Reform Bill   Rewarding Providers   Public Option Policy Brief   Health Reform & Abortion   Delivery System Reform

This Article Figures Only Full Text (HTML) Reprint (PDF) Online Supplement Submit a response to this article Comments: View responses Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in Web of Science Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Berndt, E. R. Articles by Tuttle, E. Search for Related Content PubMed Articles by Berndt, E. R. Articles by Tuttle, E. Related Collections Legal/Regulatory Issues Business Of Health Pharmaceuticals Research And Technology Health Spending Consumer Issues

Health Tracking

MARKETWATCH

Authorized Generic Drugs, Price Competition, And Consumers’ Welfare

The growing frequency of authorized generics has important implications for the welfare of prescription drug consumers. Authorized generic entry could affect the timing of generic entry, brand-name and generic prices, and generic penetration. We reviewed 1999–2003 data and found that generic entry in the absence of short-run exclusivity restrictions benefits consumers through lower short-run prices. We suggest that these benefits likely also result from authorized generics. We posit that long-run prices and shares are likely essentially unaffected by authorized generics and that potential costs to consumers from any delayed generic entry are likely small.

                      What's this?

This article has been cited by other articles:

				M. J. Higgins and S. J. H. Graham Balancing Innovation and Access: Patent Challenges Tip the Scales Science, October 16, 2009; 326(5951): 370 - 371. [Abstract] [Full Text] [PDF]

				M. Aitken, E. R. Berndt, and D. M. Cutler Prescription Drug Spending Trends In The United States: Looking Beyond The Turning Point Health Aff., January 1, 2009; 28(1): w151 - w160. [Abstract] [Full Text] [PDF]

				H. G. Grabowski and J. L. Moe Impact of Economic, Regulatory, and Patent Policies on Innovation in Cancer Chemoprevention Cancer Prevention Research, July 1, 2008; 1(2): 84 - 90. [Abstract] [Full Text] [PDF]

Comments: